PRIM, S.A. (PRM) AI Stock Analysis

PRIM, S.A.

(BME:PRM)

Select Model

Rating:76Outperform

Price Target:EUR 15.00▲(20.97% Upside)

Action:reiterated

Date:08/04/26

Overall score is driven primarily by strong financial positioning—especially the debt-free balance sheet and improving profitability—offset by uneven cash-flow consistency and a 2025 free-cash-flow step-down. Technicals are supportive with price above key moving averages, though near-term momentum looks stretched (very high stochastic). Valuation is a positive contributor with a moderate P/E and a solid dividend yield.

Positive Factors

Debt-free balance sheetBeing effectively unlevered provides durable financial flexibility: lower interest burden, more optionality for capex, dividends or bolt-on M&A, and greater resilience to cyclical shocks. Over the next 2–6 months this supports stable operations and strategic optionality.

Negative Factors

Uneven cash generationIntermittent negative operating and free cash flow in prior years plus a 2025 FCF step-down versus 2024 signal that cash conversion is inconsistent. This reduces the reliability of internally funded growth and increases sensitivity to working-capital swings and capex over the medium term.

PRIM, S.A. (PRM) vs. iShares MSCI Spain ETF (EWP)

Market Cap: EUR 210.17M
Dividend Yield: 4.06%
Average Volume (3M): 3,735
Price to Earnings (P/E): 16.3
Beta (1Y): 0.26
Revenue Growth: 4.20%
EPS Growth: -10.44%
Country: Spain
Employees: 959
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Instruments & Supplies

PRIM, S.A. Business Overview & Revenue Model

Company Description

Prim, S.A., operating through its various affiliated entities, specializes in the conception, production, and sale of orthopedic solutions. These items are utilized across diverse fields such as physical therapy, aquatic therapies (like thalassothera...

How the Company Makes Money

PRIM, S.A. makes money primarily by selling healthcare and medical-technology products to professional and institutional customers (e.g., hospitals, clinics, pharmacies, orthopedic and rehabilitation centers) as well as through retail channels where...

PRIM, S.A. Financial Statement Overview

Summary

Strong balance sheet (debt reduced to zero by 2025 and growing equity) supports financial flexibility. Income statement trends are positive with consistent revenue growth and improved 2025 profitability, but margin volatility over the period is a quality concern. Cash flow is the main drag: while 2025 operating/free cash flow is positive, cash generation has been uneven historically and 2025 free cash flow stepped down versus 2024 with weaker cash conversion vs net income.

Income Statement

78Positive

Balance Sheet

90Very Positive

Cash Flow

62Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	250.65M	251.82M	233.15M	216.51M	197.25M	168.51M
Gross Profit	124.50M	127.01M	112.62M	45.30M	94.56M	83.08M
EBITDA	29.07M	33.94M	26.23M	28.05M	19.71M	30.09M
Net Income	13.03M	16.68M	10.92M	12.67M	8.39M	17.42M
Balance Sheet
Total Assets	209.04M	196.53M	190.28M	200.10M	184.99M	179.85M
Cash, Cash Equivalents and Short-Term Investments	25.42M	23.03M	13.75M	13.25M	14.94M	36.54M
Total Debt	14.89M	16.28M	18.50M	25.48M	22.07M	19.07M
Total Liabilities	71.50M	58.89M	61.34M	74.28M	65.28M	58.38M
Stockholders Equity	137.54M	137.64M	128.93M	125.82M	119.71M	121.47M
Cash Flow
Free Cash Flow	23.44M	18.14M	10.76M	-20.09M	-7.02M	13.87M
Operating Cash Flow	36.74M	30.46M	22.11M	-11.33M	4.89M	26.30M
Investing Cash Flow	-11.06M	-10.07M	-7.59M	-3.67M	-14.10M	-8.70M
Financing Cash Flow	-13.43M	-11.62M	-11.32M	10.46M	-12.19M	-15.09M

PRIM, S.A. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

ES:PRM against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ES:PRM	76Outperform	EUR 210.17M	16.35	9.47%	4.06%	4.20%	-10.44%
ES:PHM	73Outperform	EUR 1.20B	20.69	23.64%	1.48%	15.52%	34.76%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ES:ATRY	47Neutral	EUR 198.30M	-2.03	-65.08%	―	-53.44%	-296.14%
ES:ORY	45Neutral	EUR 198.99M	-77.82	-2.23%	―	―	53.50%

* Healthcare Sector Average

Performance Comparison

ES:PRM and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
ES:PRM	PRIM, S.A.	12.40	-1.06	-7.85%
ES:ORY	Oryzon Genomics	2.43	-1.07	-30.63%
ES:PHM	Pharma Mar SA	67.50	-4.57	-6.34%
ES:ATRY	Atrys Health SA	2.61	-0.63	-19.44%
ES:LAB	Labiana Health SA	5.20	0.88	20.48%
ES:STNA	Santa Ana Global Enterprises SA	15.40	1.80	13.24%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 04, 2026

PRIM, S.A. AI Stock Analysis